About OCUMENSION-B Company

We are a Chinese ophthalmology platform company dedicated to identifying, developing and commercializing first-of-its-kind or best-in-class ophthalmic treatments. Our vision is to provide world-class overall pharmaceutical solutions to meet the huge demand gap in ophthalmology care in China. We believe that our ophthalmology platform, which has a clear first-mover advantage, will enable us to take a leading position in the Chinese ophthalmology industry. With our platform, we have built a comprehensive, innovative and proven ophthalmic drug portfolio carefully designed at a strategic level. As of the date of this report, we have 18 drug assets covering all major anterior and posterior eye conditions. We have five major drug candidates in the phase III clinical trial development stage in China. We believe that if approved, these candidates may be the first of their kind or the best in their class, and will show significant short-term earnings potential as early as 2022. Our product portfolio includes three of the ten ophthalmic drugs approved by the FDA since 2015 but not marketed in China using any process. Additionally, our product portfolio includes three drugs that are in or near commercialization. The table below provides an overview of our product portfolio and individual drug asset status as of the date of this report.